Isofol Medical Ab Stock Net Income
| ISOFOL Stock | SEK 0.70 0.01 1.45% |
As of the 28th of January, Isofol Medical retains the insignificant Risk Adjusted Performance, market risk adjusted performance of (0.06), and Standard Deviation of 2.06. Isofol Medical technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Isofol Medical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Isofol Medical's valuation are provided below:Isofol Medical AB does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Isofol |
Isofol Medical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Isofol Medical's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Isofol Medical.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Isofol Medical on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Isofol Medical AB or generate 0.0% return on investment in Isofol Medical over 90 days. Isofol Medical is related to or competes with Annexin Pharmaceuticals, IRLAB Therapeutics, Lipum AB, Initiator Pharma, Karolinska Development, Enorama Pharma, and Bio Works. Isofol Medical AB , a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and i... More
Isofol Medical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Isofol Medical's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Isofol Medical AB upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 8.53 | |||
| Value At Risk | (2.82) | |||
| Potential Upside | 2.86 |
Isofol Medical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Isofol Medical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Isofol Medical's standard deviation. In reality, there are many statistical measures that can use Isofol Medical historical prices to predict the future Isofol Medical's volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.06) | |||
| Total Risk Alpha | (0.23) | |||
| Treynor Ratio | (0.07) |
Isofol Medical January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.06) | |||
| Mean Deviation | 1.62 | |||
| Coefficient Of Variation | (9,401) | |||
| Standard Deviation | 2.06 | |||
| Variance | 4.24 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.06) | |||
| Total Risk Alpha | (0.23) | |||
| Treynor Ratio | (0.07) | |||
| Maximum Drawdown | 8.53 | |||
| Value At Risk | (2.82) | |||
| Potential Upside | 2.86 | |||
| Skewness | 0.4501 | |||
| Kurtosis | (0.26) |
Isofol Medical AB Backtested Returns
At this point, Isofol Medical is dangerous. Isofol Medical AB holds Efficiency (Sharpe) Ratio of 0.0221, which attests that the entity had a 0.0221 % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Isofol Medical AB, which you can use to evaluate the volatility of the firm. Please check out Isofol Medical's insignificant Risk Adjusted Performance, market risk adjusted performance of (0.06), and Standard Deviation of 2.06 to validate if the risk estimate we provide is consistent with the expected return of 0.0469%. Isofol Medical has a performance score of 1 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.46, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Isofol Medical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Isofol Medical is expected to be smaller as well. Isofol Medical AB right now retains a risk of 2.13%. Please check out Isofol Medical total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Isofol Medical will be following its current trending patterns.
Auto-correlation | -0.41 |
Modest reverse predictability
Isofol Medical AB has modest reverse predictability. Overlapping area represents the amount of predictability between Isofol Medical time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Isofol Medical AB price movement. The serial correlation of -0.41 indicates that just about 41.0% of current Isofol Medical price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.41 | |
| Spearman Rank Test | 0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Isofol Medical AB reported net income of (200.25 Million). This is 158.68% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all Sweden stocks is 135.07% higher than that of the company.
Isofol Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Isofol Medical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Isofol Medical could also be used in its relative valuation, which is a method of valuing Isofol Medical by comparing valuation metrics of similar companies.Isofol Medical is currently under evaluation in net income category among its peers.
Isofol Fundamentals
| Return On Equity | -0.69 | |||
| Return On Asset | -0.36 | |||
| Operating Margin | (13.09) % | |||
| Current Valuation | (42.41 M) | |||
| Shares Outstanding | 161.52 M | |||
| Shares Owned By Insiders | 25.71 % | |||
| Shares Owned By Institutions | 12.47 % | |||
| Price To Book | 0.65 X | |||
| Price To Sales | 7.45 X | |||
| Revenue | 22.41 M | |||
| Gross Profit | (174.31 M) | |||
| EBITDA | (198.49 M) | |||
| Net Income | (200.25 M) | |||
| Cash And Equivalents | 379.45 M | |||
| Cash Per Share | 0.93 X | |||
| Total Debt | 110 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 1.21 X | |||
| Book Value Per Share | 1.14 X | |||
| Cash Flow From Operations | (188.43 M) | |||
| Earnings Per Share | (1.42) X | |||
| Target Price | 1.31 | |||
| Number Of Employees | 15 | |||
| Beta | 1.56 | |||
| Market Capitalization | 109.18 M | |||
| Total Asset | 401.36 M | |||
| Net Asset | 401.36 M |
About Isofol Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Isofol Medical AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Isofol Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Isofol Medical AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Isofol Stock
Isofol Medical financial ratios help investors to determine whether Isofol Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isofol with respect to the benefits of owning Isofol Medical security.